Development of native, intact, and top/down technologies

-Conducted structural analysis of key oncogenic proteins to support X-ray crystallography and cryo-electron microscopy (Cryo-EM).-Collaborated with cross-functional teams to design and execute experiments aimed at elucidating the structural basis of protein function and its role in cancer development.-Applied advanced computational modeling techniques to interpret experimental data and generate structural models of protein complexes.-Prepared reports and presentations to cross-functional teams to contribute to the understanding of oncogenic mechanisms and potential therapeutic targets.

-Led GLP-compliant pharmacokinetic (PK) studies to profile drug candidates in animal models, focusing on tissue and blood distribution.-Designed and executed study protocols, ensuring compliance with regulatory guidelines and quality standards.-Developed and validated analytical methods for quantifying drug concentrations in various matrices using LC-MS/MS and other analytical techniques.-Analyzed PK data and generated comprehensive reports to support drug development decision-making.-Collaborated with cross-functional teams to interpret PK results and optimize drug candidate selection and dosing strategies.-Utilized mass spectrometry (MS) techniques to characterize sodium channel proteins, focusing on identifying and quantifying post-translational modifications (PTMs) and novel binding sites.-Developed and optimized MS methods for the analysis of complex protein samples, including sample preparation, chromatographic separation, and data acquisition.-Collaborated with research teams to design experiments and interpret MS data to elucidate the structure-function relationships of sodium channel proteins.-Applied mass spectrometry (MS) techniques to characterize the cystic fibrosis transmembrane conductance regulator (CFTR) protein expressed after treatment with lipid nanoparticle (LNP)-delivered mRNA in cell culture, animal models, and human samples.-Developed and optimized MS methods for the analysis of CFTR protein, including sample preparation, chromatographic separation, and data analysis.-Collaborated with multidisciplinary teams to design experiments and interpret MS data to understand the expression, structure, and function of CFTR protein in different models.-Identified and quantified post-translational modifications (PTMs) and protein-protein interactions of CFTR to elucidate its role in cystic fibrosis pathophysiology.

-Led activity-based ATP probe profiling of endogenous key kinases before and after non-covalent engagement with small molecules for drug potency and specificity screening.-Developed and optimized assays to assess kinase activity and small molecule engagement using activity-based probes and mass spectrometry.-Collaborated cross-functionally to design and execute experiments aimed at identifying and validating drug targets for various diseases.-Analyzed and interpreted complex data sets to assess drug potency and specificity, contributing to lead optimization and candidate selection.-Conducted drug stability and metabolite profiling from human liver microsomes, and lipid analysis from tissue samples using mass spectrometry (MS) and chromatography techniques.-Developed and validated analytical methods for the quantification of drug metabolites and lipids, ensuring data accuracy and reliability.-Collaborated with multidisciplinary teams to design and execute studies aimed at understanding drug metabolism and lipid homeostasis.

-Managed a state-of-the-art proteomics core facility, providing high-quality proteomics services and support to over 40 research groups across multiple institutes.-Collaborated with researchers to design and implement proteomics experiments, including sample preparation, mass spectrometry analysis, and data interpretation.-Established and maintained standard operating procedures (SOPs) for proteomics workflows, ensuring quality control and data reproducibility.-Mentored and trained staff and researchers in proteomics techniques and data analysis tools.Managed budget, equipment maintenance, and facility operations to ensure efficient and effective service delivery.

-Led the development of an extensive clinical blood assay capable of quantifying over 3500 blood proteins from less than 10 microliters of human plasma, enabling high-throughput biomarker discovery and validation studies.-Conducted global identification of circulating glycoproteins, employing mass spectrometry-based proteomics and glycoproteomics techniques to profile glycoprotein signatures associated with pancreatic cancer and other diseases.-Discovered novel circulating glycoproteins for the early diagnosis of pancreatic cancer, contributing to the development of a minimally invasive diagnostic test.-Performed statistical analysis of a biomarker panel for the highly sensitive and specific diagnosis of pancreatic cancer, validating its clinical utility and potential for early detection.-Published research findings in high-impact journals and presented at scientific conferences to advance the field of clinical proteomics and biomarker discovery for cancer diagnostics.

-Developed a highly sensitive and accurate targeted quantification technique for the pre-clinical assessment of pharmacokinetic parameters for therapeutic proteins from tissue and blood of animal models, enabling precise measurement of drug levels and evaluation of drug efficacy.-Conducted global discovery proteomics pharmacodynamic studies after a single-dose drug administration in animal models, elucidating activated signaling pathways and supporting pharmacokinetic/pharmacodynamic (PK/PD) modeling.-Utilized stable isotope labeling by amino acids in cell culture (SILAC) experiments for protein homeostasis analysis, providing insights into drug mechanism of action and potential biomarkers.-Employed nLC-Orbitrap mass spectrometry for sequencing therapeutic proteins, ensuring accurate characterization and quality control of biopharmaceutical products.-Published research findings in peer-reviewed journals and presented at scientific conferences to advance the field of proteomics and pharmacokinetics in drug development.

-Led LC/MS identification of oxidative drug metabolites, employing state-of-the-art mass spectrometry techniques to elucidate metabolic pathways and identify potential toxic or pharmacologically active metabolites.-Developed SRM-based quantification methods for drug metabolites, enabling precise measurement of metabolite concentrations in biological samples and supporting pharmacokinetic studies.-Designed and optimized in vitro assays for studying oxidative drug metabolism by Cytochrome P450 enzymes, providing valuable insights into drug-drug interactions and metabolic stability.-Collaborated with multidisciplinary teams to interpret data and guide drug development strategies, ensuring the safety and efficacy of pharmaceutical compounds.-Published research findings in high-impact journals and presented at scientific conferences to advance the field of drug metabolism and analytical chemistry.